The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The London-listed company’s application, as announced on 20 February of this year, continues to be processed by the FCA, though the approval process has extended beyond the anticipated timeframe, according to GSTechnologies’ corporate update?
Market makers seem to be able to operate with complete impunity. The share price here is a good example. It's being manipulated every which way, all in the name of making a market. Luckily cows aren't milked anywhere near as much.... Only my opinion.
This was the primary reason for Synairgens research which had good results from the phase 2 trial. (Southampton, UK - 24 July 2019: Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces an update on the Company's wholly-owned inhaled interferon beta (IFN-beta) programme, currently in a Phase II clinical trial, which is aimed at countering the adverse effects of common cold and influenza viruses in patients with chronic obstructive pulmonary disease (COPD) ). So how do the latest trial results effect their initial research purpose?
It would appear that Pfizer is quite ruthless when it comes to selling it's vaccine to the world. No reason to believe that they will be any different with this pill. You can bet they have pulled out all stops to get these pills to market before Synairgen's product.
https://www.washingtonpost.com/world/2021/10/19/secret-vaccine-contracts-with-governments-pfizer-took-hard-line-push-profit-report-says/